What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Compare › Victoza vs Saxenda

Victoza vs Saxenda

Victoza and Saxenda are the same molecule — liraglutide. They are sold under separate FDA applications (NDA022341 and NDA206321), which is why they carry different approved indications, different labels and different supply records. On the regulatory record they are distinct products with an identical active ingredient.

Victoza Saxenda
Active ingredientliraglutideliraglutide
FDA applicationNDA022341NDA206321
First FDA action2010-01-252014-12-23
SponsorNovo NordiskNovo Nordisk
EU authorisationVictozaSaxenda
FDA supply statusNo open records1 to be discontinued
FDA actions on file2920
Active trials of the molecule1717

Everything above is a field from Drugs@FDA, the FDA Drug Shortage Database, the EMA register or ClinicalTrials.gov. There is no efficacy comparison here and there will not be one: head-to-head claims belong to the trials that made them, and which drug suits a particular person is a question for a clinician.

Full records: Victoza · Saxenda · liraglutide